Sixteen Combinations Withdrawn: India Returns to the Irrational FDC Problem
Antibiotic pairings without clinical justification are the sharpest driver of resistance a regulator can actually remove — a decade after the last mass ban
What happened
Drug regulation questions usually reward listing institutions. This one rewards a distinction: not all combination drugs are irrational, and the boundary between the two is evidentiary rather than pharmacological. Learn why fixed-dose combinations exist legitimately in tuberculosis and HIV treatment, and why the same format becomes an antimicrobial resistance driver when assembled without trial evidence — because that contrast is the entire regulatory argument.
Rational vs Irrational Combinations
The Regulatory Line
| Rational FDC | Irrational FDC | |
|---|---|---|
| Evidence for pairing | Clinical trial data | None |
| Why combined | Synergy, resistance suppression, adherence | Product differentiation |
| Typical example | TB and HIV regimens | Unjustified antibiotic pairings |
| Net effect | Better outcomes, fewer missed doses | All the risks, none of the proven benefit |
| FDCs prohibited | 16 |
| Dominated by | Antibiotic + dermatological |
| Regulator / statute | CDSCO · Drugs & Cosmetics Act, 1940 |
| Previous mass ban | 2016 — hundreds, heavily litigated |
Source: Central Drugs Standard Control Organisation; Indian Council of Medical Research
A fixed-dose combination (FDC) is a formulation containing two or more active pharmaceutical ingredients in a fixed ratio in a single dosage form.
●The regulatory question is not the format but the evidence.
●Rational FDCs are supported by clinical data showing the combination is more effective, safer or materially improves adherence — the standard examples being anti-tuberculosis regimens and antiretroviral therapy for HIV, where multi-drug treatment is mandatory and a single pill reduces the risk of patients taking some components and not others, which itself breeds resistance.
●Irrational FDCs combine ingredients without trial evidence for the pairing, typically to create a differentiated product or to extend a brand, and they carry the risks of both components with the demonstrated benefit of neither.
●The apex regulator is the Central Drugs Standard Control Organisation (CDSCO), headed by the Drugs Controller General of India, acting under the Drugs and Cosmetics Act, 1940 and its Rules.
●In 2016 the government prohibited hundreds of FDC formulations in a landmark exercise that was subsequently litigated at length.
●The Indian Council of Medical Research has repeatedly flagged irrational combinations, particularly antibiotic pairings, as a driver of antimicrobial resistance (AMR). The present order prohibits sixteen FDCs, dominated by antibiotic combinations and dermatological products, with examples including amoxicillin with serratiopeptidase and norfloxacin with tinidazole.
The problem is not combination but justification — the same format that makes tuberculosis treatment work becomes a resistance driver when the pairing has never been tested.
◎ In Simple Words
Some medicines contain two or more drugs mixed into one tablet. Sometimes that is genuinely useful — TB and HIV treatment work this way, because patients must take several drugs together and one pill is easier to remember. But sometimes companies combine drugs just to create a product to sell, without testing whether the mixture actually helps. This is especially dangerous with antibiotics, because using them unnecessarily makes bacteria resistant, so the medicines stop working for everyone. The government has now banned sixteen such combinations.
Factual Pointers
Practice · 2 questions
With reference to fixed-dose combination (FDC) drugs, consider the following statements:
1. All fixed-dose combinations are considered irrational and are discouraged by regulators.
2. Anti-tuberculosis and antiretroviral therapies commonly use fixed-dose combinations.
3. The Central Drugs Standard Control Organisation regulates such drugs under the Drugs and Cosmetics Act, 1940.
Which of the statements given above are correct?
Why are irrational antibiotic fixed-dose combinations of particular concern for antimicrobial resistance?
Mains Practice Questions
"The problem with fixed-dose combinations is not combination but justification." Examine the regulatory distinction between rational and irrational FDCs and its public health significance. (250 words, GS2)
A formulation ban is the tractable half of the antimicrobial resistance problem. Critically examine India's AMR strategy in this light. (250 words, GS3)
Discuss the procedural requirements that determine whether a drug prohibition survives judicial scrutiny, with reference to the 2016 FDC ban. (150 words, GS2)
Frequently Asked
· People also askWhat is a fixed-dose combination drug?
A formulation containing two or more active pharmaceutical ingredients in a fixed ratio in a single dosage form. Regulators distinguish rational FDCs, supported by clinical evidence that the combination performs better than its components separately, from irrational ones assembled without such evidence.
Prelims · GS3The distinction is evidentiary rather than pharmacological — the same format is indispensable in tuberculosis and HIV therapy and problematic when the pairing has never been tested.
SOURCE Central Drugs Standard Control Organisation
What has been banned and why?
Sixteen fixed-dose combinations have been prohibited on grounds of safety and efficacy, in a list dominated by antibiotic combinations and dermatological products. Examples cited include amoxicillin with serratiopeptidase and norfloxacin with tinidazole.
Prelims · GS2Such products carry the adverse-effect profile of every component with the demonstrated benefit of none, and antibiotic pairings additionally accelerate antimicrobial resistance.
SOURCE CDSCO, Ministry of Health and Family Welfare
Why are irrational antibiotic combinations especially dangerous?
Because they expose bacterial populations to two antibiotics simultaneously without clinical justification. Selection pressure then operates on both at once, so a single unnecessary course can compromise more than one future treatment option — and resistance, once acquired, spreads.
GS3 · HealthThe Indian Council of Medical Research has repeatedly identified this as a distinct AMR driver, separate from over-prescription of single agents.
SOURCE Indian Council of Medical Research
If FDCs are problematic, why are they used for TB and HIV?
Because multi-drug treatment is mandatory in both, and a single pill reduces the risk of patients taking some components and not others — partial adherence being itself a major driver of drug resistance. These combinations are supported by clinical evidence, which is what makes them rational.
GS3 · HealthRational combination rests on demonstrable synergy, resistance suppression or complementary action, together with compatible pharmacokinetics so the ingredients can sensibly share a fixed ratio.
SOURCE World Health Organization treatment guidelines
What happened with the 2016 FDC ban?
The government prohibited hundreds of formulations in a landmark exercise that was then litigated extensively, with manufacturers challenging both the process and the evidentiary basis. Portions of the order were unwound or delayed for years.
GS2 · GovernanceThe lesson is procedural: prohibitions resting on documented expert evaluation, with manufacturers given opportunity to present data, survive judicial scrutiny — which is why a smaller, well-evidenced list is more defensible than a larger one.
SOURCE CDSCO; litigation record
Will banning products solve antimicrobial resistance?
No — it addresses only the supply side. India's AMR burden is driven equally by over-the-counter dispensing without prescription, incomplete courses, and antibiotic use in animal husbandry, none of which a formulation ban touches.
GS3 · HealthThere is also a market-structure problem: combinations allow product differentiation in a crowded generic market, so unless approval pathways require combination-specific evidence at licensing, banned products are replaced by newly formulated ones.
SOURCE National Action Plan on AMR